Logo image of RENB

RENOVARO INC (RENB) Stock Fundamental Analysis

NASDAQ:RENB - Nasdaq - US29350E1047 - Common Stock - Currency: USD

0.4017  +0.05 (+13.93%)

After market: 0.404 +0 (+0.57%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to RENB. RENB was compared to 568 industry peers in the Biotechnology industry. The financial health of RENB is average, but there are quite some concerns on its profitability. RENB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RENB has reported negative net income.
In the past year RENB has reported a negative cash flow from operations.
RENB had negative earnings in each of the past 5 years.
In the past 5 years RENB always reported negative operating cash flow.
RENB Yearly Net Income VS EBIT VS OCF VS FCFRENB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -106.35%, RENB is not doing good in the industry: 77.99% of the companies in the same industry are doing better.
With a Return On Equity value of -144.30%, RENB is not doing good in the industry: 62.32% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -106.35%
ROE -144.3%
ROIC N/A
ROA(3y)-72.08%
ROA(5y)-46.53%
ROE(3y)-85.62%
ROE(5y)-54.83%
ROIC(3y)N/A
ROIC(5y)N/A
RENB Yearly ROA, ROE, ROICRENB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

RENB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RENB Yearly Profit, Operating, Gross MarginsRENB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for RENB has been increased compared to 1 year ago.
Compared to 5 years ago, RENB has more shares outstanding
RENB has a better debt/assets ratio than last year.
RENB Yearly Shares OutstandingRENB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RENB Yearly Total Debt VS Total AssetsRENB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RENB has an Altman-Z score of -4.53. This is a bad value and indicates that RENB is not financially healthy and even has some risk of bankruptcy.
RENB's Altman-Z score of -4.53 is in line compared to the rest of the industry. RENB outperforms 42.25% of its industry peers.
There is no outstanding debt for RENB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.53
ROIC/WACCN/A
WACCN/A
RENB Yearly LT Debt VS Equity VS FCFRENB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

RENB has a Current Ratio of 0.06. This is a bad value and indicates that RENB is not financially healthy enough and could expect problems in meeting its short term obligations.
RENB's Current ratio of 0.06 is on the low side compared to the rest of the industry. RENB is outperformed by 97.89% of its industry peers.
A Quick Ratio of 0.06 indicates that RENB may have some problems paying its short term obligations.
With a Quick ratio value of 0.06, RENB is not doing good in the industry: 97.71% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
RENB Yearly Current Assets VS Current LiabilitesRENB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

RENB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.17%.
EPS 1Y (TTM)-32.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RENB Yearly Revenue VS EstimatesRENB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 0 0 0 0 0

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RENB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RENB Price Earnings VS Forward Price EarningsRENB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RENB Per share dataRENB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RENB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RENOVARO INC

NASDAQ:RENB (4/21/2025, 8:00:01 PM)

After market: 0.404 +0 (+0.57%)

0.4017

+0.05 (+13.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13
Earnings (Next)05-13 2025-05-13
Inst Owners14.02%
Inst Owner ChangeN/A
Ins Owners11.28%
Ins Owner Change-9.27%
Market Cap71.26M
AnalystsN/A
Price TargetN/A
Short Float %6.96%
Short Ratio3.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.46
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.35%
ROE -144.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-72.08%
ROA(5y)-46.53%
ROE(3y)-85.62%
ROE(5y)-54.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -4.53
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.76%
Cap/Depr(5y)253.9%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.88%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.9%
OCF growth 3YN/A
OCF growth 5YN/A